Details of the Drug Combinations

General Information of This Drug (ID: DM1P6FR)

• Drug Name: ARRY-162 (DM1P6FR)
• Synonyms: 606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME

Indication

Melanoma; ICD 11: 2C30; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arry-162 + Panobinostat	DCSHCGD	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]

17 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arry-162 + LEE011	DC993H4	LEE011	Solid Tumors Harboring a BRAF V600 Mutation	[3]
Arry-162 + Alpelisib	DC4O3K4	Alpelisib	Advanced and Selected Solid Tumors	[4]
Arry-162 + LGX818	DC93UVB	LGX818	Solid Tumors Harboring a BRAF V600 Mutation	[3]
Arry-162 + LEE011	DCPPDY6	LEE011	Locally Advanced or Metastatic NRAS Mutant Melanoma	[5]
Arry-162 + Crizotinib	DC096TP	Crizotinib	Solid Tumor	[6]
Arry-162 + Sotrastaurin acetate	DC47C7H	Sotrastaurin acetate	Uveal Melanoma	[7]
Arry-162 + Pexidartinib	DC47IF5	Pexidartinib	Gastrointestinal Stromal Tumor (GIST)	[8]
Arry-162 + Lorlatinib	DCATITY	Lorlatinib	Lung Cancer	[9]
Arry-162 + Erlotinib	DCLMQ1W	Erlotinib	Lung Cancer	[10]
Arry-162 + Brigatinib	DCPHL38	Brigatinib	ALK Gene Rearrangement	[11]
Arry-162 + Hydroxychloroquine	DCZ4PQJ	Hydroxychloroquine	Metastatic Pancreatic Adenocarcinoma	[12]
Talazoparib + Arry-162	DCNKPA6	Talazoparib	Pancreatic Cancer	[13]
Arry-162 + Palbociclib	DC792WE	Palbociclib	Metastatic Colorectal Carcinoma	[14]
Arry-162 + Palbociclib	DC9QCOH	Palbociclib	Malignant Solid Neoplasm	[15]
Arry-162 + Belinostat	DCRIDTP	Belinostat	Metastatic Uveal Melanoma	[16]
Fulvestrant + Arry-162	DCIOVZW	Fulvestrant	Anatomic Stage IV Breast Cancer AJCC v8	[17]
Arry-162 + LGX818	DCKBZVO	LGX818	Melanoma	[18]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT01543698) A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
• [4] ClinicalTrials.gov (NCT01449058) A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
• [5] ClinicalTrials.gov (NCT01781572) A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
• [6] ClinicalTrials.gov (NCT02510001) MEK and MET Inhibition in Colorectal Cancer
• [7] ClinicalTrials.gov (NCT01801358) A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
• [8] ClinicalTrials.gov (NCT03158103) A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
• [9] ClinicalTrials.gov (NCT04292119) Lorlatinib Combinations in Lung Cancer
• [10] ClinicalTrials.gov (NCT01859026) A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
• [11] ClinicalTrials.gov (NCT04005144) Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
• [12] ClinicalTrials.gov (NCT04132505) Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
• [13] ClinicalTrials.gov (NCT03637491) A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
• [14] ClinicalTrials.gov (NCT03981614) Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
• [15] ClinicalTrials.gov (NCT05554367) Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
• [16] ClinicalTrials.gov (NCT05170334) Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
• [17] ClinicalTrials.gov (NCT05554354) Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
• [18] ClinicalTrials.gov (NCT01909453) Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma